Comparative effectiveness of first-line nab-paclitaxel versus paclitaxel monotherapy in triple-negative breast cancer

Patricia Luhn, Stephen Y. Chui, Angela Fu Chi Hsieh, Jingbo Yi, Almut Mecke, Preeti S. Bajaj, Waseem Hasnain, Adeline Falgas, Thanh G.N. Ton, Allison W. Kurian

    Research output: Contribution to journalArticle


    Aim: This observational study evaluated the effectiveness of nab-paclitaxel versus paclitaxel monotherapy as first-line (1L) treatment for metastatic triple-negative breast cancer (mTNBC). Materials & methods: 200 patients from the US Flatiron Health electronic health record-derived database (mTNBC diagnosis, January 2011-October 2016) who received 1L nab-paclitaxel (n = 105) or paclitaxel (n = 95) monotherapy were included. Overall survival and time to next treatment were evaluated. Results: The adjusted overall survival hazard ratio was 0.98 (95% CI: 0.67-1.44), indicating a similar risk of death between groups. Adjusted time to next treatment hazard ratio was 0.89 (95% confidence interval: 0.62-1.29). Conclusion: Nab-paclitaxel and paclitaxel monotherapy showed similar efficacy, suggesting their interchangeability as 1L treatments for mTNBC.

    Original languageEnglish (US)
    Pages (from-to)1173-1185
    Number of pages13
    JournalJournal of Comparative Effectiveness Research
    Issue number14
    Publication statusPublished - Jan 1 2019



    • comparative effectiveness
    • first-line treatment
    • metastatic triple-negative breast cancer
    • nab-paclitaxel
    • paclitaxel

    ASJC Scopus subject areas

    • Health Policy

    Cite this